安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2009 Financial . . .
ImmunoGen, Inc (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced financial results for the three-month period ended December 31, 2008 – the second quarter of the Company’s 2009 fiscal year
- SEC Filing | ImmunoGen, Inc.
830 Winter Street, Waltham, MA 02451 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781) 895-0600Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A 2 below):
- ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2010 Financial . . .
WALTHAM, Mass , Jan 28, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended December 31, 2009 - the second quarter of the Company's
- SGO 2023 - ImmunoGen
IMMUNOGEN IS NOW PART OF ABBVIE Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline
- SEC Filing | ImmunoGen, Inc.
Immunogen Inc (Name of Issuer) Common (Title of Class of Securities) 45253H101 (CUSIP Number) March 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b) o Rule 13d-1(c) o
- ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial . . .
WALTHAM, Mass --(BUSINESS WIRE)--Aug 6, 2009-- ImmunoGen, Inc (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the fiscal year and three-month period ended June 30, 2009
- | ImmunoGen, Inc.
The Investor Relations website contains information about ImmunoGen, Inc 's business for stockholders, potential investors, and financial analysts
- SEC Filing | ImmunoGen, Inc.
Use these links to rapidly review the document TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No 333-216438 PROSPECTUS Up to $50,000,000
|
|
|